This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017;35:893–911.
O’Donnell M, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, et al. Acute myeloid leukemia guidelines 2017. J Natl Compr Canc Netw. 2017;15:926–57.
Curigliano G, Cardinale D, Suter T, Plataniotis G, Azambuja ED, Sandri MT, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23 suppl 7:vii155–66.
Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27:911–39.
Zamorano JL, Lancellotti P, Muñoz DR, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J 2016;37:2768–80.
Volkova M, Russell R. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev. 2012;7:214–20.
Lotrionte M, Biondi-Zoccai G, Abbate A, Lanzetta G, Dascenzo F, Malavasi V, et al. Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity. Am J Cardiol. 2013;112:1980–4.
Anderlini P, Benjamin RS, Wong FC, Kantarjian HM, Andreeff M, Kornblau SM, et al. Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. J Clin Oncol. 1995;13:2827–34.
Khan H, Gardner K, Shaw C, Halpern A, Huebner E, Percival ME, et al. Table 1 is original data that cannot be found in other documents. It was analyzed for the purpose of this submitted letter to the editor titled “Need for routine examination of left ventricular ejection fraction in patients with AML”. Leukemia in press.
Thavendiranathan P, Abdel-Qadir H, Fischer HD, Liu Y, Camacho X, Amir E, et al. Risk-imaging mismatch in cardiac imaging practices for women receiving systemic therapy for early-stage breast cancer: a population-based cohort study. J Clin Oncol. 2018;36:2980–7.
Dang CT, Yu AF, Liu J, Steingart R. Risk-imaging mismatch: why is there a disconnect? J Clin Oncol. 2018;36:2975–7.
Peddi P, Master SR, Dwary AD, Ravipati HP, Patel AH, Pasam A, et al. Utility of routine pretreatment evaluation of left ventricular ejection fraction in breast cancer patients receiving anthracyclines. Breast J. 2018;25:62–8.
Author information
Authors and Affiliations
Contributions
EE and HK conceived the project, analyzed data, and wrote the paper. KG and CS provided data. AH, EH, MP, SM, MS, RW, and PB provided suggestions.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Khan, H.M., Gardner, K.M., Shaw, C. et al. Need for routine examination of left ventricular ejection fraction in patients with AML. Leukemia 34, 1169–1171 (2020). https://doi.org/10.1038/s41375-019-0637-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-019-0637-z